Smart deals start with the right connections.
Access 800+ qualified LPs through CQ’s Investor Database.
EMBLEM Enterprise Management Technology Transfer GmbH
Corporate (with an investment arm)
EMBLEM, established in 1999, is the wholly owned subsidiary and exclusive technology and knowledge transfer partner of the European Molecular Biology Laboratory (EMBL). It manages over 1,000 inventions, 450 patents, and 400 active licensing contracts in the pharmaceutical, biotech, and instrumentation markets.
Overview and Management
Establishment Year
1999
Mission
Committed to bridging the gap between academia and industry by supporting researchers in protecting and commercializing their discoveries, and promoting the commercial utilization of scientific results and innovations.
Values
Innovation, collaboration, and dedication to advancing scientific discoveries into practical applications.
Investment Roles
Direct Investor,Intermediary
Participant Demographics
Partners with EMBL scientists, alumni, external contributors, and industry players in the pharmaceutical, biotech, and instrumentation sectors.
Generational Wealth Planning
Risk Tolerance
References or Case Studies
Testimonials from EMBL scientists and collaborators underline the firm's professionalism and contribution to successful projects.
Team Experience
Team includes professionals with expertise in intellectual property, business, and research.
Notable Achievements
Over 1,000 inventions managed, 450 patent applications and granted patents, and 400 active license contracts.
Project Track Record
Co-founded more than 20 companies, including DenovAI Biotech, ALPX, BIOSAXS, and others.
Exit Strategies
Licensing technologies to established companies or supporting spin-offs for commercialization.
Legal, Compliance and Contact Information
Regulatory Registrations
GDPR-compliant.
Compliance History
No major violations reported.
info@embl-em.de
Phone Number
+49 (0) 6221 363 22 10
Address
Heidelberg Germany